`
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Park, Sam <SPark@winston.com>
`Friday, September 29, 2017 12:19 PM
`Trials
`Parmelee, Steve; jmills@wsgr.com; mrosato@wsgr.com; jlove@gibsondunn.com; ahollis@kirkland.com;
`egoryunov@kirkland.com; greg.springsted@kirkland.com; RTrenchard@gibsondunn.com
`RE: IPR2017-01929 motion for joinder
`
`Your Honors,
`
`I am the lead counsel for Petitioners Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE (“Sun”) in
`IPR2017‐01929.
`
` write to inform the Board that counsel for joined petitioners Actavis Elizabeth LLC and Teva Pharmaceuticals USA, Inc. (collectively “Actavis”),
`independently, has informed Sun that Actavis does not oppose Sun’s motion to join IPR2017‐00854. Sun agrees to the same conditions as set forth
`in Paper 23 of IPR2017‐00854.
`
`Please let me know if you need any additional information. I have copied counsel for Patent Owner, Apotex, and Actavis to this correspondence.
`
`
`Respectfully submitted,
`Sam Park (Reg. No. 59,656)
`Lead Counsel for Sun
`
`
` I
`
`Samuel S. Park
`Partner
`Winston & Strawn LLP
`35 W. Wacker Drive
`Chicago, IL 60601-9703
`D: +1 312-558-7931
`F: +1 312-558-5700
`Bio | VCard | Email | winston.com
`Admitted to practice in Illinois, New York, U.S. Patent & Trademark Office
`
`
`
`1
`
`
`
`Please consider the environment before printing this e-mail.
`
`From: Trials [mailto:Trials@USPTO.GOV]
`Sent: Wednesday, September 27, 2017 12:38 PM
`To: Park, Sam <SPark@winston.com>; jlove@gibsondunn.com
`Cc: Trials <Trials@USPTO.GOV>; Parmelee, Steve <sparmelee@wsgr.com>
`Subject: IPR2017‐01929 motion for joinder
`
`Counsel,
`
`On September 26, 2017, a representative of Petitioner Sun Pharma called to inquire about the status of their motion for joinder with IPR2017-00854, filed August
`16, 2017. Paper 3. The time for Patent Owner to oppose the motion under 37 C.F.R. § 42.25(a)(1) has expired. Sun Pharma indicates that lead Petitioner of
`IPR2017-00854, Apotex, does not oppose the motion. Id. at 2; see also, id. at n.1 (indicating that joined Petitioner Argentum also does not oppose).
`
`On September 9, 2017, we issued an Order further joining Actavis Elizabeth LLC and Teva Pharmaceuticals USA, Inc. (collectively “Actavis”) to this
`proceeding. See IPR2017-00854, Paper 23. To expedite our consideration of its motion, Sun Pharma should indicate if lead Petitioner Apotex speaks for Actavis,
`or if Actavis, independently, does not oppose the motion and agrees to the same conditions as set forth in Paper 23 of IPR2017-00854.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`
`
`
`
`The contents of this message may be privileged and confidential. If this message has been received in error, please delete it without reading it. Your receipt of this message is not intended to waive any applicable
`privilege. Please do not disseminate this message without the permission of the author. Any tax advice contained in this email was not intended to be used, and cannot be used, by you (or any other taxpayer) to avoid
`penalties under applicable tax laws and regulations.
`
`2
`
`